Compounds studied for metabolic, ranked by the strength of the evidence — strongest at the top, research-grade and disappointing below. Grades reflect the evidence, not marketing. This is a neutral reference; nothing here is a recommendation to use, and no compound is offered for sale.
Liraglutide is the pioneer GLP-1 — the first in wide use and the first approved for obesity (Saxenda, 2014), the drug that opened the field for semaglutide and tirzepatide.
Semaglutide is a GLP-1 receptor agonist and one of the most-prescribed medicines in the world — FDA-approved for type-2 diabetes (Ozempic), obesity (Wegovy) and oral T2D…
Tesamorelin is a stabilized 44-amino-acid GHRH analog and the only GHRH analog with a current FDA approval (as Egrifta, for HIV-associated lipodystrophy since 2010).
Tirzepatide is a dual GIP/GLP-1 agonist and, in the only head-to-head obesity trial (SURMOUNT-5), produced greater weight loss than semaglutide (−20.2% vs −13.7%).
Amycretin is Novo Nordisk's first-in-class unimolecular GLP-1 + amylin agonist — the CagriSema concept in a single molecule, developed as both a pill and a weekly injection.
Cagrilintide is a long-acting amylin analog — a genuinely different mechanism from the GLP-1 drugs, acting on amylin/calcitonin receptors in the brainstem.
Orforglipron is the first oral small-molecule GLP-1 — a non-peptide pill, taken anytime without food/water restrictions, that in Phase 3 delivered semaglutide-level weight loss…
Retatrutide is Eli Lilly's investigational triple GLP-1/GIP/glucagon agonist ("triple-G"), which in Phase 3 (TRIUMPH-1) produced the deepest weight loss of any obesity candidate…
MOTS-c is a 16-amino-acid mitochondrial-derived peptide, encoded in mtDNA and discovered in 2015, that regulates metabolism largely through the AMPK pathway.
Ranking is by evidence grade (A–F), the same ceiling shown on each compound page — not by popularity or margin. No dosing, reconstitution, or administration is given anywhere on Vallydia. See each entry for its full evidence table and legal status by region.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.